Several other research analysts have also weighed in on FIXX. Zacks Investment Research lowered shares of Homology Medicines from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Robert W. Baird lifted their price target on Homology Medicines from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, March 13th. Royal Bank of Canada began coverage on Homology Medicines in a research note on Wednesday, May 13th. They set an “outperform” rating and a $30.00 price objective on the stock. FIX assumed coverage on Homology Medicines in a research report on Thursday, June 25th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Oppenheimer upgraded Homology Medicines from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a report on Sunday, March 15th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Homology Medicines currently has an average rating of “Buy” and a consensus price target of $30.67.
NASDAQ:FIXX opened at $15.01 on Wednesday. The firm has a 50-day moving average of $15.10 and a two-hundred day moving average of $16.54. Homology Medicines has a 1-year low of $11.05 and a 1-year high of $24.00.
Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.09). The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.68 million. Homology Medicines had a negative net margin of 5,816.28% and a negative return on equity of 44.92%. As a group, sell-side analysts expect that Homology Medicines will post -3.05 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of FIXX. State Street Corp increased its position in Homology Medicines by 2.0% in the first quarter. State Street Corp now owns 835,357 shares of the company’s stock worth $12,981,000 after buying an additional 16,088 shares during the period. Vivo Capital LLC acquired a new position in shares of Homology Medicines during the first quarter valued at $15,673,000. Advisor Group Holdings Inc. bought a new position in shares of Homology Medicines during the first quarter worth about $319,000. Invesco Ltd. acquired a new stake in shares of Homology Medicines in the 1st quarter worth about $542,000. Finally, Cormorant Asset Management LP bought a new stake in Homology Medicines in the 1st quarter valued at about $9,324,000. Hedge funds and other institutional investors own 81.86% of the company’s stock.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
See Also: Federal Reserve
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.